The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm predicted the immunotherapeutic response of MINDY2 in PC and discovered that the higher the expression of MINDY2, the better the response of PC to immune checkpoint inhibitors (Figure 1I). This evidence concerns the gene MINDY2 and pachyonychia congenita.